medicina
Article
Effects of a Pedometer-Based Walking Program in Patients with
COPD—A Pilot Study
Yen-HueyChen1,2,3,* ,Li-RongChen4,Ching-ChingTsao5 ,Yu-ChengChen5andChung-ChiHuang1,2,3
1 DepartmentofRespiratoryTherapy,CollegeofMedicine,ChangGungUniversity,
TaoyuanCity33302,Taiwan;cch4848@adm.cgmh.org.tw
2 DivisionofPulmonaryandCriticalCareMedicine,ChangGungMemorialHospital,Linko,
TaoyuanCity33353,Taiwan
3 DepartmentofRespiratoryCare,ChangGungUniversityofScienceandTechnology,Chiayi61363,Taiwan
4 MasterDegreePrograminHealthcareIndustry,CollegeofMedicine,ChangGungUniversity,
TaoyuanCity33302,Taiwan;lena5114@gmail.com
5 DivisionofPulmonaryandCriticalCareMedicine,DepartmentofInternalMedicine,
TaoyuanGeneralHospital,TaoyuanCity33004,Taiwan;n002286@gmail.com(C.-C.T.);
chenxanzai@gmail.com(Y.-C.C.)
* Correspondence:yhchen@mail.cgu.edu.tw;Tel.:+886-3-2118-800(ext.5233);Fax:+886-3-2118-421
Abstract: Backgroundandobjectives: Patientswithchronicobstructivepulmonarydisease(COPD)
sufferfromimpairedpulmonaryfunctionanddyspnea,whichresultinlimitedlevelsofphysical
activity,andimpairedqualityoflife. Exerciseandregularphysicalactivityhavebeenprovento
breaktheviciouscircle.Theaimofthispilotstudyistoinvestigatetheeffectsofawalkingprogram
onexercisecapacityandqualityoflifeinpatientswithCOPD.MaterialsandMethods:Patientswith
COPDwererandomlyassignedtoapedometergroup(PG)orcontrolgroup(CON).Subjectsinthe
PGwalkedtargetstepsdailywithapedometerforsixweeks. Beforeandaftertheprogram,the
(cid:1)(cid:2)(cid:3)(cid:1)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:1) followingmeasurementswereperformed:pulmonaryfunctiontest(PFT),dailysteps,Six-Minute
(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)
WalkTest(6MWT),COPDAssessmentTest(CAT),andqualityoflifequestionnaire(SF-12).Results:
Citation:Chen,Y.-H.;Chen,L.-R.; Afterthiswalkingprogram,PG(n=15)significantlyimprovedtheirdailystepsfrom4768.4±2643.3
Tsao,C.-C.;Chen,Y.-C.;Huang,C.-C. stepsto7042.7±4281.9steps(p=0.01). Forcedvitalcapacity(FVC)increasedfrom2.5±0.7Lto
EffectsofaPedometer-Based
2.8±0.9L(p=0.02).CATscoresdecreasedfrom14.9±8.8pointsto11.5±7.5points(p=0.03).In
WalkingPrograminPatientswith
thecontrolgroup(n=11),therewerenodifferencesinanyoutcomesafterthisdailywalkingprogram.
COPD—APilotStudy.Medicina2022,
Conclusions:ForpatientswithCOPD,adailywalkingprogramwithapedometerisbeneficialinthe
58,490. https://doi.org/10.3390/
improvementofpulmonaryfunction,dailysteps,andqualityoflife.
medicina58040490
AcademicEditor:PatrickGeraghty
Keywords:COPD;pedometer;physicalactivity;qualityoflife
Received:21February2022
Accepted:24March2022
Published:29March2022
1. Introduction
Publisher’sNote:MDPIstaysneutral
Chronic obstructive pulmonary disease (COPD), a leading cause of mortality and
withregardtojurisdictionalclaimsin
morbidityworldwide,isprojectedtorisefrom5.4millionin2005to8.3millionin2030[1–3].
publishedmapsandinstitutionalaffil-
IntheUnitedStates,COPDwasthethirdmostcommoncauseofdeathandtheonlydisease
iations.
amongthetop10thatcontinuedtoincreaseinprevalence[4,5]. Aninternationalguideline
statesthatregularphysicalactivityisbeneficialforCOPDpatientsbyimprovingsymptoms,
functionalindependence,andqualityoflife[1].
Copyright: © 2022 by the authors. However, physical inactivity is a major clinical feature of COPD. As the disease
Licensee MDPI, Basel, Switzerland. progresses,COPDcausesbreathlessness,fatigue,andexerciseintolerance,resultinginthe
This article is an open access article reductionofphysicalactivitylevels. Decreasedphysicalactivitylevelsareoftenassociated
distributed under the terms and withpoorlungfunction,musclestrengthdecline,impairedqualityoflife,andfrequencyof
conditionsoftheCreativeCommons hospitalization[6,7].
Attribution(CCBY)license(https://
Interventions to increase the physical activity level of COPD patients are essential
creativecommons.org/licenses/by/
fortheimprovementofprognosis. Inpatientand/oroutpatientpulmonaryrehabilitation
4.0/).
Medicina2022,58,490.https://doi.org/10.3390/medicina58040490 https://www.mdpi.com/journal/medicina
Medicina2022,58,490 2of10
programshavebeenproventoimproveexercisecapacityandqualityoflifeinpatients
withCOPD[8]. GuidelinesforthemanagementofCOPDhavesuggestedthatpulmonary
rehabilitationincludingexerciseshouldbeprovided[8]. However,therearebarriersfor
COPDpatientsparticipatinginhospital-basedpulmonaryrehabilitationprograms,suchas
transportationrequirements,geographicdistancefromthehospital,andadherencetothe
pulmonaryrehabilitationprogram[9,10]. Thus,thereisaneedtofindaconvenientand
effectiveinterventiontopromotephysicalactivityforCOPD.
Walkingisacommonphysicalactivityandisessentialfortheindependenceofper-
formingactivitiesindailylife. Dailystepsandtimespentonthestepshavebeensuggested
as indicators of functional capacity [11]. Pedometers are easy to use and can provide
feedbacktoindividualsabouttheirdailyactivities. Studiesshowedthatpedometersare
an effective tool to monitor and increase physical activity in healthy populations [12].
However,itisunclearwhethertheuseofpedometershassimilarbenefitsinCOPDpopula-
tions. Theprimarypurposeofthisstudywastoexaminetheeffectsofapedometer-based
homewalkingprogramonthelevelsofphysicalactivity. Thesecondaryoutcomewasto
determineitseffectsonpulmonaryfunction,symptoms,andqualityoflife.
2. MaterialsandMethods
2.1. StudyParticipants
Thiswasaprospective,randomizedstudy. Werecruitedpatientswithaclinicaldi-
agnosisofCOPDreferredtothepulmonaryrehabilitationprogramfromthepulmonary
outpatient department of the Tao-Yuan General Hospital, Ministry of Health and Wel-
fare, Taiwan, if they met the following criteria: (1) diagnosed with COPD according to
theGlobalInitiativeforChronicObstructiveLungDisease(GOLD)criteria[13];(2)ina
medicallystablecondition(i.e., atleastfourweekssincethelastexacerbation), (3)able
towalkunassisted,and(4)≥40yearsofage. Theexclusioncriteriawerereceivinghome
oxygentherapy,hemodynamicinstability,otherpulmonarydiseases,andcomorbidities
thataffectphysicalactivitiesindailylifesuchassevereneurological,musculoskeletal,or
cardiovascularconditions. ThestudywasperformedinaccordancewiththeDeclaration
ofHelsinkiandwasapprovedbythehospital’sinstitutionalreviewboard(TYGH106081).
Writteninformedconsentwasobtainedfromallpatientspriortoinclusion. Basicdatasuch
asdemographics,anthropometrics,anddiagnoseswererecordedatthetimeofadmission
tothestudy.
2.2. StudyDesign
Thesubjectswererandomlyassignedtotheinterventionorcontrolgroupaccordingto
acomputer-generatedalgorithm. Subjectswererandomlyassignedtoeitherthepedometer
group(PG)orcontrolgroup(CON).
Inthepedometergroup,patientsreceivedapedometerandthetaskofwalkingathome
forsixweeks. Theyattachedapedometer(whichshowsthenumberofsteps)ontheirwrist
forapproximately12h(fromawakeninguntilgoingtobed)eachday,sevendays/weekfor
sixweeks. Theywerealsoaskedtowalkathomeasmuchaspossibletotrytoreachthe
targetdailysteps. Thetargetstepsweresetas100–110%oftheiraveragedailystepsfrom
thepreviousweek,withthefirstweek’stargetderivedfromthebaselinemeasurement,
eventuallyupto10,000steps. Theinvestigatorsaskedforpatients’subjectiveresponses
andcheckedthepatients’pedometersduringweeklyvisits. Theinvestigatorsthenreset
thetargetstepforthefollowingweekaccordingtothepatients’responsesandpedometer
dailystepcount. Inthecontrolgroup,patientsreceivedcounselingduringweeklyvisits
forsixweeks. Patientswereencouragedtobeactiveathomeandwalk≥30minperday
withoutanysupervision. Bothgroupsreceivedthesamestandardmedicalcarefromtheir
chestphysician,whichconsistedofstandardmonitoringandself-referralconsultationif
anysymptomsworsened.
Medicina2022,58,490 3of10
2.3. Measurements
Atthebeginningandendofthestudy,thefollowingwereassessed:
Pulmonaryfunctionwasassessedasforcedvitalcapacity(FVC),forcedexpiratory
volumeinonesecond(FEV1),FEV1/FVC,and%FEV1measuredbyaspirometerfollowing
themethodreportedbytheATSrecommendations[14].
ThesubjectivesensationofbreathlessnesswasassessedusingthemodifiedMedical
ResearchCouncil(mMRC)scale. ThemMRCdyspneascalecontainsfivestatementsthat
patientsrateonascaleof0–4reflectingminimal(e.g.,“Ionlygetbreathlesswithstrenuous
exertion”)toseveresymptoms(e.g.,“Iamtoobreathlesstoleavethehouse”)[15].
Exercisecapacitywasmeasuredbya6minwalkingtestandexpressedasthe6min
walkdistance(6MWD).Thetestwasperformedbyawell-trainedrespiratorytherapist
accordingtotheATSrecommendations[16].
Thelevelofphysicalactivitywasassessedasthenumberofdailysteps,definedas
theaveragestepcountofsevendaysobtainedbythepedometer. Ataweekbeforeand
aftercompletionofthestudy,allsubjectswereaskedtowearworethepedometerforseven
continuousdays. Theinvestigatorsthemcollectedpedometerandrecordedtheaverage
dailystepsfromthepedometerdata.
QualityoflifestatuswasassessedusingtheCOPDAssessmentTest(CAT)andshort
form 12 (SF-12) questionnaires. The CAT questionnaire is a disease-specific quality of
life questionnaire. It has eight items related to symptoms, energy, sleep, and activity.
According to the CAT, the degree of impact from diseases can be classified into four
levels: slightimpact(score0–10),mediumimpact(score11–20),highimpact(score21–30),
and very high impact (score > 30) [17]. The SF-12 questionnaire is a short version of
theShortForm36questionnaire,whichisagenericqualityoflifequestionnaireandhas
beenappliedtobothhealthypopulationsandpatientswithchronicdiseases. TheSF-12
questionnairecontains12itemsontwoscales:physical(PCS)andmentalhealthcomponent
scale(MCS)[12]. TheSF-12explainsthemajorityofthevariance(80–85%)oftheSF-36. The
outcomesrangefrom0(worstconceivableQOL)to100(bestconceivableQOL)[18].
2.4. Statistics
Theprimaryoutcomeofthestudywasachangeindailystepcount,anindicatorof
PA.Thesamplesizewascalculatedbasedonobservationsfromapreviousstudy,assuming
a mean difference in daily step count of 725 steps per day between the groups [19]. A
sample size of 31 subjects per group would be needed, yielding an analysis power of
80%, setting α to 0.05. The analysis was conducted using SPSS v.18 (SPSS, Chicago, IL,
USA). The Shapiro–Wilk test was used to examine the normality of distribution. The
resultswereexpressedasthemean ± SDfornominaldistributionsandasmedianand
interquartilerange. (25–75percentiles)fornonparametricdistributions. Student’st-test
orMann–WhitneyUtestwasusedwhenappropriatetoexaminethebaselinedifferences
betweengroupsandpairedt-testorWilcoxonsigned-ranktestwasusedtoexaminewithin-
groupdifferences. Statisticalsignificancewassetatp<0.05.
3. Results
Fifty-nineconsecutiveeligiblepatientswerescreenedfromMarch2018toMarch2019
(Figure1). Fourteenpatientswereexcludedbecausetheydidnotmeettheinclusioncriteria
(n=14).Thus,45subjectswererandomizedintoboththepedometergroup(PG,n=21)and
controlgroup(CG,n=24). Duringthestudyperiod,sixsubjectsinthePGand13subjects
intheCGdroppedoutofthestudyduetocomorbidities(musculoskeletal,cardiovascular,
andthecommoncold)orlackofmotivation,leaving15subjectsinthePGand11subjects
intheCGforanalysis(Figure1).
Medicina2022,58,490 4of10
Medicina 2022, 58, x FOR PEER REVIEW 4 of 11
Figure1.Flowchartofsubjectparticipationandanalysis.
Figure 1. Flow chart of subject participation and analysis.
Table1presentsasummaryofthedemographicandclinicalcharacteristicsofthepar-
Table 1 presents a summary of the demographic and clinical characteristics of the
ticipants. Nosignificantdifferencesexistedbetweenthegroupsintermsofage(73.5±8.2
participants. No significant differences existed between the groups in terms of age (73.5 ±
vs. 71.9±11.1years,p=0.678),andBMI(0.2±4.4vs. 1.0±2.3kg/m2,p=0.443). The
8.2 vs. 71.9 ± 11.1 years, p = 0.678), and BMI (0.2 ± 4.4 vs. 1.0 ± 2.3 kg/m2, p = 0.443). The
majorityofsubjectsinbothgroupswerediagnosedwithCOPDGOLDstageII(53.3%in
majority of subjects in both groups were diagnosed with COPD GOLD stage II (53.3% in
PGand63.6%inCG).Therewerenosignificantdifferencesinthebaselinecharacteristics
PG and 63.6% in CG). There were no significant differences in the baseline characteristics
betweenthePGandCGexceptthe%ofpredicted6minwalkingdistance.
between the PG and CG except the % of predicted 6 min walking distance.
InthePG,therewasasignificantimprovementinpulmonaryfunction,dailysteps,
dyspnea scale, and quality of life at the end of the study. The predicted % of FVC sig-
Table 1. Demographic data of subjects in pedometer (PG) and control group (CG).
nificantly increased from 81.0 ± 14.3% to 90.6 ± 23.4% (p = 0.021) (Table 2). The daily
stepsincrea sedfrom4768.4P±G2 6(n4 3=. 315st)e psto7042C.7G± (4n2 =8 11.19) steps(p=0.01)(pF igure2A).
Post-CGAoTlds cno (r%es) (11.5 ± 7.5) wer e significantly lower t han those in the pre0-.C70A T scores
(14.9±8.8)II( Figure2B).Inthe8 c(5o3n.3tr%ol) group,therew7(e6r3e.6n%o) significantdiffere ncesinthe
measurementofpulmonaryfunction,6minwalkingdistance,dyspneascale,andquality
III 7 (46.7%) 4(36.4%)
oflifescorebetweenpre-andpost-measurements. Thenumberofdailystepsdecreased
Gender 1.00
from4468.08±3783.9stepsto4385.1±3692.6steps(p>0.05)(Figure2A).
Male 13 (86.7%) 9 (81.8%)
Afterthestudy,subjectsinthePGshowedasignificantimprovementinthedailysteps
Female 2 (13.3%) 2(18.2%)
(2274.3±3014.2steps)comparedwiththoseintheCG(−83.68±923.30steps)(p=0.011)
Age (year) 73.5 ± 8.2 71.9 ± 11.1 0.678
(Table3). TherewasalsoasignificantdifferenceinthechangesinCATscoresbetweenthe
Body height (cm) 163.5 ± 6.8 163.0 ± 9.2 0.881
PG(−4.80±6.6)andCG(1.55±6.5)(p=0.022)(Table3). Nosignificantdifferencewas
Body weight (kg) 59.0 ± 10.9 56.2 ± 10.0 0.512
foundinthechangesinpulmonaryfunction,6minwalkingdistance,anddyspneascale
betweBeMnIt h(kegP/Gm2a)n dCGatthe22e.n2d ± o4f.4t hestudy(Tab2le1.30) ±. 2.3 0.443
Pulmonary function test
FEV1 (L) 1.2 ± 0.4 1.3 ± 0.6 0.718
Predicted FEV1(%) 51.2 ± 13.7 53.0 ± 16.3 0.750
FVC (L) 2.5 ± 0.7 2.8 ± 1.1 0.299
Predicted FVC(%) 81.0±14.3 84.3 ± 32.5 0.751
FEV1/FVC (%) 49.8 ± 15.2 47.7 ± 19.0 0.762
mMRC score 1.5 ± 1.1 1.6 ± 0.7 0.829
Exercise capacity
Medicina2022,58,490 5of10
Table1.Demographicdataofsubjectsinpedometer(PG)andcontrolgroup(CG).
PG(n=15) CG(n=11) p
Goldn(%) 0.70
II 8(53.3%) 7(63.6%)
III 7(46.7%) 4(36.4%)
Gender 1.00
Male 13(86.7%) 9(81.8%)
Female 2(13.3%) 2(18.2%)
Age(year) 73.5±8.2 71.9±11.1 0.678
Bodyheight(cm) 163.5±6.8 163.0±9.2 0.881
Bodyweight(kg) 59.0±10.9 56.2±10.0 0.512
BMI(kg/m2) 22.2±4.4 21.0±2.3 0.443
Pulmonaryfunctiontest
FEV1(L) 1.2±0.4 1.3±0.6 0.718
PredictedFEV1(%) 51.2±13.7 53.0±16.3 0.750
FVC(L) 2.5±0.7 2.8±1.1 0.299
PredictedFVC(%) 81.0±14.3 84.3±32.5 0.751
FEV1/FVC(%) 49.8±15.2 47.7±19.0 0.762
mMRCscore 1.5±1.1 1.6±0.7 0.829
Exercisecapacity
6MWD(m) 450.5±102.4 397.8±110.9 0.153
%ofpredicted6MWD 115.2±25.9% 74.5±37.5% 0.014
Dailysteps(steps) 4768.4±2643.3 4468.8±3783.9 0.700
Qualityoflife
SF12PCS 35.5±10.2 38.2±7.1 0.608
SF12MCS 48.7±10.9 46.8±10.3 0.550
Table2.Comparisonsofoutcomeswithinpedometer(PG)andcontrolgroup(CG).
PG CG
Pre Post p Pre Post p
Pulmonaryfunction
FEV1(L) 1.2±0.4 1.2±0.4 0.181 1.3±0.6 1.3±0.6 0.859
PredictedFEV1(%) 51.2±13.7 53.7±15.9 0.222 53.0±16.3 51.6±16.1 0.831
FVC(L) 2.5±0.7 2.8±0.9 0.022* 2.8±1.1 2.9±1.1 0.823
PredictedFVC(%) 81.0±14.3 90.6±23.4 0.021* 84.3±32.5 90.5±24.6 0.439
FEV1/FVC(%) 49.8±15.2 47.5±15.9 0.210 47.7±19.0 47.6±20.1 0.891
Dyspnea
mMRC 1.5±1.1 1.6±1.1 0.50 1.6±0.7 1.8±0.9 0.192
Exercisecapacity
6MWD(m) 450.5±102.4 450.0±108.4 0.969 397.8±110.9 412.2±108.8 0.212
%ofpredicted6MWD 115.2±25.9% 114.6±26.6% 0.815 74.5±37.5% 74.4±38.1% 0.992
Qualityoflife
SF12PCS 35.5±10.2 38.4±9.8 0.189 38.2±7.1 41.1±10.3 0.168
SF12MCS 48.7±10.9 50.8±10.3 0.310 46.8±10.3 46.9±12.0 0.991
6MWD:6minwalkingdistance.SF12PCS:Shortform12Physiologiccomponentsection.SF12PCS:Shortform
12Mentalcomponentsection.*:p<0.05.
MMeeddiicciinnaa 22002222,, 5588,, 4x9 F0OR PEER REVIEW 66 ooff 1101
,
,
Figure2.Comparisonsofdailysteps(A)andCATscores(B)withinsubjectsinPGandCG.*:p<0.05.
Figure 2. Comparisons of daily steps (A) and CAT scores (B) within subjects in PG and CG. *: p <
Table3.Comparisonofchangesinparametersbetweenpedometer(PG)andcontrolgroup(CG).
0.05.
PG CG p
After the study, subjects in the PG showed a significant improvement in the daily
∆FEV1(L) 0.06±0.16 −0.01±0.17 0.310
steps (2274.3 ± 3014.2 steps) compared with those in the CG (−83.68 ± 923.30 steps) (p =
∆PredictedFEV1(%) 2.55±7.6 −1.44±7.3 0.192
0.011)(T∆a Fb Vle
C
3 () L. )There was also
0
a
.2
8si ±gn 0i .f 4i 0cant differenc 0e
.
0i 2n ±th 0e
.3
c 2hanges in CA 0T
.
0s 8c 1ores be-
twe∆en
P
rt eh de
i
cP teG
d
( F− V4 C.80
(%
±
)
6.6) and C 9G
.6
( 71±.55 14±
.
36.5) (p = 0.022)
6
.( 1T 5a±ble
25
3 .1). No significan 0t
.
6d 5i 0fference
was f∆oFuEnVd1 /inFVthCe( %ch)anges in pu−lm2.2o6n±ar6y. 7function, 6 m−i0n.0 w9±alk2.i3ng distance, a0n.d32d3yspnea
sc∆alDe ybseptnweaeesnca tleh-em PMGR aCnd CG at0 .t1h3e± en0d.7 4of the study (0T.a21bl±e 30.)5. 8 0.745
∆6MWD(meter) −0.53±50.0 12.6±39.4 0.481
Tabl∆ eD 3a. iClyomsteppasri(ssotenp osf) changes 2in2 7p4a.3ra± m3et0e1r4s. 2between pe− d8o3m.7et± er9 (2P3G.3) and control 0g.r0o1u1p* (CG).
∆CAT −4.80±6.06 1.55±6.5 0.022*
∆SF12P CS 2.96±8.0PG 3.51±6.4 CG 0.859 p
∆SF12MCS 2.1±7.4 −0.05±14.1 0.629
ΔFEV1(L) 0.06 ± 0.16 −0.01 ± 0.17 0.310
6MWD:6minwalkingdistance.SF12PCS:Shortform12Phyisologiccomponentsection.SF12PCS.Shortform
ΔPredicted FEV1 (%) 2.55 ± 7.6 −1.44 ± 7.3 0.192
12Mentalcomponentsection.*:p<0.05.
ΔFVC (L) 0.28 ± 0.40 0.02 ± 0.32 0.081
ΔPredicted FVC (%) 9.67 ± 14.3 6.15 ± 25.1 0.650
TherelationshipbetweenchangesintheparametersispresentedinTable4. Changes
ΔFEV1/FVC (%) −2.26 ± 6.7 −0.09 ± 2.3 0.323
in daily steps were significantly correlated with changes in the MRC scale (r = 0.385,
p=Δ0.D04y7s)pnanead sCcaAleT-mscMorReCs (r = 0.505,0.p13= ±0 0.0.7140 ). A greater in0c.r2e1a s±e 0i.5n8d aily step0s.7w45a s
associaΔte6d MwWithDg (rmeaetteerr)i mprovement−in0.5th3e ±d 5y0s.p0 neascaleands1y2m.6p ±to 3m9.-4re latedqua0l.i4ty81o f
lifequΔeDstaiiolyn nsateirpes s(csoterepss.) 2274.3 ± 3014.2 −83.7 ± 923.3 0.011 *
ΔCAT −4.80± 6.06 1.55 ± 6.5 0.022 *
Table4.ThΔeScFor1r2e lPatCioSn betweenchangeso2f.9p6a r±a m8.e0t ersinallsubjects.3.51 ± 6.4 0.859
ΔSF12 MCS 2.1 ± 7.4 −0.05 ± 14.1 0.629
∆DailySteps ∆CAT
6 MWD: 6 min walking distance. SF12 PCS: Short form 12 Phyisologic component section. SF12 PCS.
Short form ∆ 12F EMVe1n(tLal) component section. *: p <0 0.0.0753. 0.399
∆PredictedFEV1(%) 0.200 0.439*
∆FVC(L) 0.287 0.356
The relationship between changes in the parameters is presented in Table 4. Changes
∆PredictedFVC(%) 0.180 0.289
in daily∆ s Ft Ee Vp 1s
/
w FVe Cre
(
%sig )nificantly correlated
0
.0w 96ith changes in the MRC sc 0a .0le
5
3(r = 0.385,p =
0.047) and C∆mAMT RscCores (r = 0.505, p= 0.010).0 A.38 g5r*eater increase in daily step0.s4 0w5as associated
with gr∆e6atMerW imDp(mroevteerm) ent in the dyspnea 0s.c3a8l0e and symptom-related qu0a.0li2t2y of life ques-
tionnaire∆ sDcoarileys.s teps 1 0.505*
*:p<0.05.
Medicina2022,58,490 7of10
4. Discussion
Themainfindingofthisrandomizedcontrolledtrialdemonstratedthatinpatients
withCOPD,asteptargetusingapedometer-basedhomeprogramproducedasignificant
increase in daily steps. This daily walking program also resulted in improvement of
pulmonaryfunctionandperceptionofhealthstatus. However,nosignificantimprovement
wasobservedinexercisecapacity.
Inourstudy,subjectsinthePGhadsignificantlyincreasesinFVCandFVC%after
theintervention,whereassubjectsinCGshowednosignificantdifferences(Table2). In
addition, although it was not statistically significant, the changes in % predicted FEV1
inPGshowedatendencyofincrease,whereasatendencyofdecreasewasfoundinCG
(Tables2and3). Inastudyexaminingtheeffectsofaself-monitored,home-basedexercise
training program on patients with moderate COPD, subjects in the intervention group
demonstratedasignificantimprovementinFEV1%,whereassubjectsinthecontrolgroup
showedatendencyofdecreaseinFEV1%afterthe3-monthprogram[20]. Ameta-analysis
of21randomized,controlledtrialsreportedthatexercisetrainingwasassociatedwitha
smallbutsignificantincreaseinspirometryresults(e.g.,FEV1,FVC)[21]. Duringwalking,
regularandfrequentbodymovementsinducedeepbreathing,enhancechestexpansion,
increasepulmonaryventilation,andmayresultintheimprovementofpulmonaryfunction.
Theresultsofourstudyareconsistentwiththoseofapreviousstudythatshowedthat
physicalactivityisassociatedwiththeimprovementormaintenanceoflungfunctionin
COPDpatients.
ThelevelofphysicalactivityisoftendecreasedinpatientswithCOPDduetoexertion
dyspneaandexerciseintolerance,leadingtofurtherdeconditioning. Inourstudy,thedaily
steps in the PG significantly increased from 4768.4 ± 2643.3 steps/day to
7042.7±4281.9steps/dayaftera6-weekintervention. Theimprovementindailysteps
in the PG was also significantly higher than that in the CG. Mendoza et al. evaluated
the effects of a 3-month pedometer-based program on the level of physical activity in
patientswithCOPD[22]. TheyfoundthatthePGhadsignificantlygreaterimprovement
indailystepsthanthepatientsinthecontrolgroup[22]. Kawagoshietal. demonstrated
asignificantlyhigherdailywalkingtimeinCOPDpatientswhoparticipatedinahome-
basedpedometerprogramthan intheCG[23]. Thecommercializedpedometer, which
providesimmediatevisualfeedback,mayincreasesubjects’motivationandcomplianceto
accomplishthesetgoal. Withapedometer,subjectsbecomeawareoftheircurrentnumber
of steps and increase their efforts to change their behavior [24]. Our results appear to
supportpreviousfindingswhichsuggestthebenefitsofpedometer-basedprogramsonthe
improvementinthelevelofphysicalactivities.
Theeffectsofapedometer-basedprogramamongCOPDpatientshavebeenproposed
inpreviousstudies.Moyetal.setthegoalofdailystepstobeanincreaseof600steps/week
andreportedanimprovementof447steps/day(about13%)aftera16-weekhomepro-
gram [25]. In another study, the goal of daily steps was set to increase 15%/month in
theexperimentalgroupandthesubjectshaveameanchangein1114steps(36%)aftera
12-week intervention[26]. Compared to previous studies[25,26], our study achieved a
higherincreaseofdailysteps(2274steps,about47%)withashorterduration(6weeks).
Physiologicalcapacityisincreasedbyphysicaltrainingstimulusonaregularbasis. To
buildanewadaptation,thetrainingstimulusmustbeincreasedtomaintainoverload[27].
Theprescriptionoftheoverloadingdoseisalsoessentialfortheimprovementofcapacity.
Eithertoosmallortoohighoverloadingdosecouldleadtonoimprovementor,evenworth,
tissue damage. In our study, the target of daily steps was set individually (an increase
of10%ofthesubject’saveragedailystepsfromthepreviousweek)whichmaybemore
preciselyfitpatients’capacityandleadtoimprovementofdailystepswithbetterefficiency.
Inourstudy,qualityoflifewasassessedusingCATandSF12questionnaires. Thepa-
tientsinthePGdemonstratedsignificantimprovementsinCATscoresaftertheintervention
program. ThechangesinCATlevelsinthePGweresignificantlyhigherthanthoseinthe
CG.Inaddition,anincreaseinthenumberofdailystepswasassociatedwithimprovement
Medicina2022,58,490 8of10
indyspnealevel(mMRCscale)andqualityoflife(CATscores). Widyastutiaetal. reported
thatCOPDpatientsdemonstratedasignificantimprovementindailystepsandmMRC
andCATscoresaftersixweeksofahomepedometer-basedwalkingprogram[28]. Ina
studyexaminingtheeffectsofapedometer-basedprogramonCOPDpatients,Mendoza
etal. foundthattheexperimentalgroupshowedincreasedimprovementindailysteps
andCATscores[22]. Theresultsofourstudyareconsistentwiththosepreviousstudies
andsuggestedthatapedometer-basedprogramcanimprovethelevelofdailyactivityand
qualityoflifeinCOPDpatients. Regularandsustainedparticipationinphysicalactivity
(PA)canassistinthepreventionand/orslowdowntheprogressofseveralchronicdiseases
inrelationtobothprimaryandsecondaryprevention[29]. PAimprovesperipheralmuscle
functioninpatientswithCOPD[28]. Italsoreducesthenumberofhospitaladmissions,
whichhavebeenshowntoimpairQoL[30]. Theresultsofourstudywereconsistentwith
thoseofpreviousstudiesthatshowedthatCOPDpatientswhomaintainorincreasetheir
levelsofdailyactivitymaybreaktheviciouscycleofinactivityandimprovetheirQoL.
Apulmonaryrehabilitationprogramthatincludesexercisehasbeenrecommended
forpatientswithCOPDtoimprovelevelofphysicalactivityandqualityoflife[8]. Many
traditionalpulmonaryrehabilitationprogramsareheldinhospitalsandcouldbedifficult
forpatientstoaccessconsideringthetransportationrequirementsanddistancefromthe
hospitals. Overthelasttwoyears,theworldhasbeenconsumedbytheCOVID-19pan-
demic. Despitegreateffortstocontrolthepandemic,theinfectionratesarestillhighand
thehealthcaresystemfaceenormouschallengearoundtheworld. Barriersforpatientswith
COPDtoeffectivepulmonaryrehabilitationexistedpriortotheCOVID-19pandemicand
wereexacerbatedbythepandemicbecauseoftheneedforsocialdistancing,widespread
lockdowns,andoverloadonhealthcaresystems. Thepedometer-basedprograminour
studycanbefollowedathomeandthusmaylowertheriskofcontagionduringthetrans-
portationtohospital. Thisprogrammaybeconsideredtobeanalternativeprogramfor
patientstomaintaintheirphysicalfunctionduringepidemicconditions.
In a previous study, COPD patients with a mean disease severity of GOLD level
2.2demonstrated significant improvement in 6 min walking distance (6 MWD) from
404±148mto467±157mafterparticipatinginawalkingprogramwithapedometerfor
feedback[23]. However,inourstudy,nosignificantchangesin6MWD(450.5±102.4m
vs. 450.0±108.4m)werefoundaftertheinterventionprograminthePG.Thiscouldbe
duetotheceilingeffectasthemajorityofsubjectswereclassifiedasGOLDII.Spruitetal.
performed6minwalkingtestforthousandsofCOPDpatientsandreportedthatthemean
6MWD was 409 ± 112 m [31]. In our study, the mean 6 MWD of the PG at baseline
was450.5±102.4m,whichwasmuchhigherthanthatinthepreviousstudy. The%of
predicted6MWDatbaseline(115.2±25.9%)wasalreadyover100%inthePG,whichmay
resultintheceilingeffectandthusmaynotbeabletogainadditionalimprovementinthe
performanceof6minwalkingtest.
Limitation
Thisstudyhadseverallimitations. First,theself-efficacyofthesubjectsinthisstudy
was not evaluated. Second, subjects were not blinded to their group, which may have
influencedthemotivationofthesubjectsintheCG.However,bothgroupsreceivedthe
sameamountofface-to-facecontact,meaningthatdifferencesbetweengroupswerenot
duetodifferentlevelsofinputfromhealthprofessionalsbutratherwererelatedtothe
specificnatureoftheintervention. Third,thesmallsamplesizeandhighnumberofdrop
offinourstudymayhaveaffectedthestatisticalpowerofdetectingthedifferencesofthe
results. ThesmallsamplesizemayalsolimittherepresentativeabilityofCOPD.Further
studieswithlargersamplesizesshouldbecarriedout.
5. Conclusions
Inconclusion,thestudyfindingsindicatethatthepedometer-based,steptargethome
programenhancesthequalityoflifeandthelevelofphysicalactivitybyincreasingdaily
Medicina2022,58,490 9of10
stepsinpatientswithCOPD.Thesenoveldataprovidesignificantinsightsfordeveloping
anappropriatehomerehabilitationprogramforCOPDpatientsbyhealthcareproviders
withtheassistanceofcommercialdevicessuchaspedometers. Overall,ourresultssupport
theuseofspecificprogramsthatincludetheuseofmonitoringdevicesandgoalsettingto
promotepositiveoutcomesinpatientswithCOPD.
AuthorContributions:Conceptualization,Y.-H.C.,L.-R.C.;methodology,L.-R.C.,C.-C.T.,validation,
Y.-C.C.,C.-C.H.;formalanalysis,Y.-H.C.,L.-R.C.;investigation,L.-R.C.,C.-C.T.;resources,C.-C.T.,
Y.-C.C.,datacuration,L.-R.C.,C.-C.T.;writing—originaldraftpreparation,Y.-C.C.,L.-R.C.;writing—
C.-C.H.Allauthorshavereadandagreedtothepublishedversionofthemanuscript.
Funding:Thisresearchreceivednoexternalfunding.
InstitutionalReviewBoardStatement:ThestudywasperformedinaccordancewiththeDeclaration
of Helsinki and was approved by the hospital’s institutional review board (TYGH106081 on 13
February2018).
InformedConsentStatement:Informedconsentwasobtainedfromallsubjectsinvolvedinthisstudy.
DataAvailabilityStatement:Alldatawillbeavailablefromthecorrespondingauthoronreasonable
request.
Acknowledgments: The authors would also like to thank the patients and staff of Division of
PulmonaryandCriticalCareMedicine,DepartmentofInternalMedicine,TaoyuanGeneralHospital,
Taiwan.
ConflictsofInterest:Theauthorsdeclarenoconflictofinterest.
References
1. Vogelmeier,C.F.;Criner,G.J.;Martinez,F.J.;Anzueto,A.;Barnes,P.J.;Bourbeau,J.;Celli,B.R.;Chen,R.;Decramer,M.;Fabbri,L.M.
Globalstrategyforthediagnosis,management,andpreventionofchronicobstructivelungdisease2017report.GOLDexecutive
summary.Am.J.Respir.Crit.CareMed.2017,195,557–582.[CrossRef][PubMed]
2. Lozano,R.;Naghavi,M.;Foreman,K.;Lim,S.;Shibuya,K.;Aboyans,V.;Abraham,J.;Adair,T.;Aggarwal,R.;Ahn,S.Y.Global
andregionalmortalityfrom235causesofdeathfor20agegroupsin1990and2010:AsystematicanalysisfortheGlobalBurden
ofDiseaseStudy2010.Lancet2012,380,2095–2128.[CrossRef]
3. Mathers,C.D.;Loncar,D.ProjectionsofGlobalMortalityandBurdenofDiseasefrom2002to2030. PLoSMed. 2006,3,e442.
[CrossRef]
4. Mannino, D.M.; Buist, A.S.GlobalburdenofCOPD:Riskfactors, prevalence, andfuturetrends. Lancet2007, 370, 765–773.
[CrossRef]
5. Vestbo,J.;Hurd,S.S.;Agustí,A.G.;Jones,P.W.;Vogelmeier,C.;Anzueto,A.;Barnes,P.J.;Fabbri,L.M.;Martinez,F.J.;Nishimura,
M.Globalstrategyforthediagnosis,management,andpreventionofchronicobstructivepulmonarydisease:GOLDexecutive
summary.Am.J.Respir.Crit.CareMed.2013,187,347–365.[CrossRef]
6. Waschki,B.;Kirsten,A.;Holz,O.;Müller,K.-C.;Meyer,T.;Watz,H.;Magnussen,H.Physicalactivityisthestrongestpredictorof
all-causemortalityinpatientswithCOPD:Aprospectivecohortstudy.Chest2011,140,331–342.[CrossRef][PubMed]
7. Parada,A.;Klaassen,J.;Lisboa,C.;Saldías,F.;Mendoza,L.;Díaz,O.Reductionofphysicalactivityinpatientswithchronic
obstructivepulmonarydisease.Rev.Med.Chile2011,139,1562–1572.[CrossRef]
8. Spruit,M.A.;Singh,S.J.;Garvey,C.;ZuWallack,R.;Nici,L.;Rochester,C.;Hill,K.;Holland,A.E.;Lareau,S.C.;Man,W.D.-C.
AnofficialAmericanThoracicSociety/EuropeanRespiratorySocietystatement: Keyconceptsandadvancesinpulmonary
rehabilitation.Am.J.Respir.Crit.CareMed.2013,188,e13–e64.[CrossRef]
9. Fischer,M.J.;Scharloo,M.;Abbink,J.J.;van‘tHul,A.J.;vanRanst,D.;Rudolphus,A.;Weinman,J.;Rabe,K.F.;Kaptein,A.A.
Drop-outandattendanceinpulmonaryrehabilitation: Theroleofclinicalandpsychosocialvariables. Respir. Med. 2009,103,
1564–1571.[CrossRef]
10. Martinez,C.H.;Raparla,S.;Plauschinat,C.A.;Giardino,N.D.;Rogers,B.;Beresford,J.;Bentkover,J.D.;Schachtner-Appel,A.;
Curtis,J.L.;Martinez,F.J.Genderdifferencesinsymptomsandcaredeliveryforchronicobstructivepulmonarydisease.J.Women’s
Health2012,21,1267–1274.[CrossRef]
11. Boeselt,T.;Spielmanns,M.;Nell,C.;Storre,J.H.;Windisch,W.;Magerhans,L.;Beutel,B.;Kenn,K.;Greulich,T.;Alter,P.Validity
andusabilityofphysicalactivitymonitoringinpatientswithchronicobstructivepulmonarydisease(COPD).PLoSONE2016,11,
e0157229.[CrossRef][PubMed]
12. Bravata, D.M.; Smith-Spangler, C.; Sundaram, V.; Gienger, A.L.; Lin, N.; Lewis, R.; Stave, C.D.; Olkin, I.; Sirard, J.R.Using
pedometerstoincreasephysicalactivityandimprovehealth: Asystematicreview. JAMA2007,298,2296–2304. [CrossRef]
[PubMed]
Medicina2022,58,490 10of10
13. Rabe,K.F.;Hurd,S.;Anzueto,A.;Barnes,P.J.;Buist,S.A.;Calverley,P.;Fukuchi,Y.;Jenkins,C.;Rodriguez-Roisin,R.;VanWeel,
C.Globalstrategyforthediagnosis,management,andpreventionofchronicobstructivepulmonarydisease:GOLDexecutive
summary.Am.J.Respir.Crit.CareMed.2007,176,532–555.[CrossRef]
14. Miller, M.R.; Hankinson, J.; Brusasco, V.; Burgos, F.; Casaburi, R.; Coates, A.; Crapo, R.; Enright, P.; Van Der Grinten, C.;
Gustafsson,P.Standardisationofspirometry.Eur.Respir.J.2005,26,319–338.[CrossRef][PubMed]
15. Bestall,J.C.;Paul,E.A.;Garrod,R.;Garnham,R.;Jones,P.W.;AWedzicha,J.UsefulnessoftheMedicalResearchCouncil(MRC)
dyspnoeascaleasameasureofdisabilityinpatientswithchronicobstructivepulmonarydisease. Thorax1999,54,581–586.
[CrossRef]
16. ATSCommitteeonProficiencyStandardsforClinicalPulmonaryFunctionLaboratories. ATSstatement: Guidelinesforthe
six-minutewalktest.Am.J.Respir.Crit.CareMed.2002,166,111–117.[CrossRef][PubMed]
17. Cave,A.;Atkinson,L.;Tsiligianni,I.G.;Kaplan,A.AssessmentofCOPDwellnesstoolsforuseinprimarycare: AnIPCRG
initiative.Int.J.ChronicObstr.Pulm.Dis.2012,7,447–456.[CrossRef]
18. Ware,J.,Jr.;Kosinski,M.;Keller,S.D.A12-ItemShort-FormHealthSurvey: Constructionofscalesandpreliminarytestsof
reliabilityandvalidity.Med.Care1996,34,220–233.[CrossRef]
19. Clarenbach,C.F.;Sievi,N.A.;Haile,S.R.;Brack,T.;Brutsche,M.H.;Frey,M.;Irani,S.;Leuppi,J.D.;Thurnheer,R.;Kohler,M.
DeterminantsofannualchangeinphysicalactivityinCOPD.Respirology2017,22,1133–1139.[CrossRef]
20. duMoulin,M.;Taube,K.;Wegscheider,K.;Behnke,M.;vandenBussche,H.Home-basedexercisetrainingasmaintenanceafter
outpatientpulmonaryrehabilitation.Respiration2009,77,139–145.[CrossRef]
21. Salcedo,P.A.;Lindheimer,J.B.;Klein-Adams,J.C.;Sotolongo,A.M.;Falvo,M.J.Effectsofexercisetrainingonpulmonaryfunction
inadultswithchroniclungasease:Ameta-analysisofrandomizedcontrolledtrials.Arch.Phys.Med.Rehabil.2018,99,2561–2569.
[CrossRef][PubMed]
22. Mendoza,L.;Horta,P.;Espinoza,J.;Aguilera,M.;Balmaceda,N.;Castro,A.;Ruiz,M.;Díaz,O.;Hopkinson,N.Pedometersto
enhancephysicalactivityinCOPD:Arandomisedcontrolledtrial.Eur.Respir.J.2014,45,347–354.[CrossRef][PubMed]
23. Kawagoshi,A.;Kiyokawa,N.;Sugawara,K.;Takahashi,H.;Sakata,S.;Satake,M.;Shioya,T.Effectsoflow-intensityexerciseand
home-basedpulmonaryrehabilitationwithpedometerfeedbackonphysicalactivityinelderlypatientswithchronicobstructive
pulmonarydisease.Respir.Med.2015,109,364–371.[CrossRef][PubMed]
24. Riebe,D.;Ehrman,J.K.;Liguori,G.ACSMGuidelinesforExerciseTestingandPrescription,10thed.;LippincottWilliams&Wilkins:
Philadelphia,PA,USA,2017;pp.128–130.
25. Lindberg,R.Activeliving:OntheRoadwiththe10,000StepssmProgram.J.Am.Diet.Assoc.2000,100,878–879.[CrossRef]
26. Moy,M.L.;Collins,R.J.;Martinez,C.H.;Kadri,R.;Roman,P.;Holleman,R.G.;Kim,H.M.;Nguyen,H.Q.;Cohen,M.D.;Goodrich,
D.E.Aninternet-mediatedpedometer-basedprogramimproveshealth-relatedquality-of-lifedomainsanddailystepcountsin
COPD.Chest2015,148,128–137.[CrossRef]
27. Bender,B.G.;DePew,A.;Emmett,A.;Goelz,K.;Make,B.;Sharma,S.;Underwood,J.;Stempel,D.APatient-CenteredWalking
ProgramforCOPD.ChronicObstr.Pulm.Dis.2016,3,769–777.[CrossRef]
28. Widyastuti,K.;Makhabah,D.;Setijadi,A.;Sutanto,Y.S.;Ambrosino,N.Benefitsandcostsofhomepedometerassistedphysical
activityinpatientswithCOPD.Apreliminaryrandomizedcontrolledtrial.Pulmonology2018,24,211–218.[CrossRef]
29. Kesaniemi,Y.K.;Danforth,E.;Jensen,M.D.;Kopelman,P.G.;Lefèbvre,P.;Reeder,B.A.Dose-responseissuesconcerningphysical
activityandhealth:Anevidence-basedsymposium.Med.Sci.SportsExerc.2001,33,S351–S358.[CrossRef]
30. Miravitlles,M.;Ferrer,M.;Pont,À.;Zalacain,R.;Alvarez-Sala,J.L.;Masa,F.;Verea,H.;Murio,C.;Ros,F.;Vidal,R.;etal.Effectof
exacerbationsonqualityoflifeinpatientswithchronicobstructivepulmonarydisease:A2yearfollowupstudy.Thorax2004,59,
387–395.[CrossRef]
31. Spruit,M.A.;Watkins,M.L.;Edwards,L.D.;Vestbo,J.;Calverley,P.M.;Pinto-Plata,V.;Celli,B.R.;Tal-Singer,R.;Wouters,E.F.
Determinantsofpoor6-minwalkingdistanceinpatientswithCOPD:TheECLIPSEcohort. Respir. Med. 2010,104,849–857.
[CrossRef]
